Xeris Biopharma (NASDAQ:XERS) Stock Price Up 5.7% – Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s stock price was up 5.7% during mid-day trading on Friday . The stock traded as high as $3.60 and last traded at $3.55. Approximately 1,281,332 shares changed hands during trading, a decline of 8% from the average daily volume of 1,395,790 shares. The stock had previously closed at $3.36.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Monday, November 11th. HC Wainwright boosted their price objective on Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a report on Monday, November 11th.

Xeris Biopharma Trading Up 1.2 %

The company has a market cap of $506.88 million, a price-to-earnings ratio of -7.56 and a beta of 2.62. The stock has a 50 day moving average price of $3.35 and a two-hundred day moving average price of $2.91.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Walleye Capital LLC acquired a new position in Xeris Biopharma during the third quarter valued at approximately $3,197,000. Renaissance Technologies LLC grew its holdings in shares of Xeris Biopharma by 33.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after buying an additional 342,300 shares during the period. Barclays PLC increased its position in shares of Xeris Biopharma by 87.8% in the 3rd quarter. Barclays PLC now owns 324,472 shares of the company’s stock valued at $925,000 after buying an additional 151,685 shares in the last quarter. Geode Capital Management LLC raised its stake in Xeris Biopharma by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after buying an additional 93,091 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Xeris Biopharma during the third quarter worth about $237,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.